I realize you were the first one to point out West Point and the potential it has for DCVax-L, However, where I fail to comprehend the significance is this:
NWBO/Advent has the capability to make DCVax-L for the Special's program and perhaps other (new) trials, so I don't follow how WP50 fits into the overall picture unless you are saying they can handle scale. I read the Winterfell writeup, but still a bit confused.
Perhaps you can help me with the following....
What I know in simple form....A patient with GBM has an operation and has part of the tumor (lysate) removed. It is then frozen. The patient also have their blood drawn (collecting immune cells - monocytes) and both are shipped to Sawston to make DCVax-L. Depending on the amount of lysate, vaccines are made. The vaccines are then frozen and shipped (as needed) to the patient/doctor for injection. If Poly ICLC is needed to enhance the immune response wouldn't Advent perform that mixture prior to shipping to patient/doctor?
If the above is correct, then how does WP50 fit into the equation? Are you saying WP50 is just a huge Sawston facility capable of handling/storing tens of thousands of patients and also has the ability to add other adjuncts?
Thanks for answering!